AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth
This article was originally published in PharmAsia News
Executive Summary
Having endured one major patent expiry in the past year and facing several others in the near future, AstraZeneca has turned in a number of directions to offset potential losses from big sellers like Pulmicort Respules, Nexium, Seroquel, andArimidex, often with mixed results